FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 2,000 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $42.80, for a total value of $85,600.00. Following the completion of the sale, the director now owns 22,000 shares of the company’s stock, valued at $941,600. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Kalevi Kurkijarvi also recently made the following trade(s):
- On Tuesday, December 12th, Kalevi Kurkijarvi sold 12,000 shares of FibroGen stock. The stock was sold at an average price of $44.45, for a total value of $533,400.00.
- On Friday, November 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $46.65, for a total value of $93,300.00.
- On Tuesday, October 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $52.24, for a total value of $104,480.00.
Shares of FibroGen Inc (FGEN) traded up $0.55 during trading hours on Friday, reaching $49.50. The company had a trading volume of 337,707 shares, compared to its average volume of 523,167. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16. The firm has a market cap of $4,023.57, a price-to-earnings ratio of -24.26 and a beta of 1.55. FibroGen Inc has a 12 month low of $21.05 and a 12 month high of $60.15.
Hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP acquired a new position in shares of FibroGen in the second quarter valued at about $128,000. Oppenheimer Asset Management Inc. increased its holdings in shares of FibroGen by 112.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 2,336 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 696 shares during the period. BBR Partners LLC acquired a new position in shares of FibroGen in the third quarter valued at about $299,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of FibroGen in the third quarter valued at about $299,000. 57.23% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have recently commented on FGEN shares. Mizuho started coverage on FibroGen in a research report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 price target for the company. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, BidaskClub lowered FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. FibroGen presently has a consensus rating of “Buy” and an average price target of $65.67.
TRADEMARK VIOLATION WARNING: “Insider Selling: FibroGen Inc (FGEN) Director Sells 2,000 Shares of Stock” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/fibrogen-inc-fgen-director-sells-85600-00-in-stock.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.